GB0011903D0
(en)
*
|
2000-05-18 |
2000-07-05 |
Astrazeneca Ab |
Combination chemotherapy
|
US8580782B2
(en)
*
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
US20080138808A1
(en)
*
|
2003-09-11 |
2008-06-12 |
Hall Thomas A |
Methods for identification of sepsis-causing bacteria
|
US8394945B2
(en)
*
|
2003-09-11 |
2013-03-12 |
Ibis Biosciences, Inc. |
Compositions for use in identification of bacteria
|
US8546082B2
(en)
*
|
2003-09-11 |
2013-10-01 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
US8097416B2
(en)
|
2003-09-11 |
2012-01-17 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
US7767684B2
(en)
*
|
2003-11-13 |
2010-08-03 |
Abbott Laboratories |
Apoptosis promoters
|
WO2005049593A2
(en)
*
|
2003-11-13 |
2005-06-02 |
Abbott Laboratories |
N-acylsulfonamide apoptosis promoters
|
US7973161B2
(en)
|
2003-11-13 |
2011-07-05 |
Abbott Laboratories |
Apoptosis promoters
|
US8614318B2
(en)
*
|
2003-11-13 |
2013-12-24 |
Abbvie Inc. |
Apoptosis promoters
|
KR101533268B1
(ko)
*
|
2005-05-12 |
2015-07-03 |
애브비 바하마스 리미티드 |
아폽토시스 촉진제
|
US8624027B2
(en)
*
|
2005-05-12 |
2014-01-07 |
Abbvie Inc. |
Combination therapy for treating cancer and diagnostic assays for use therein
|
US20080233567A1
(en)
*
|
2006-09-05 |
2008-09-25 |
Murray William E |
Companion diagnostic assays for cancer therapy
|
US7842681B2
(en)
*
|
2006-09-05 |
2010-11-30 |
Abbott Laboratories |
Treatment of myeoproliferative diseases
|
US8168662B1
(en)
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
US8168661B2
(en)
*
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
US8178564B2
(en)
*
|
2006-11-06 |
2012-05-15 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
US8173686B2
(en)
|
2006-11-06 |
2012-05-08 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
AU2007319209B2
(en)
*
|
2006-11-15 |
2012-04-19 |
Genentech, Inc. |
Arylsulfonamide compounds
|
WO2008064116A2
(en)
*
|
2006-11-16 |
2008-05-29 |
Abbott Laboratories |
Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
|
US20100087436A1
(en)
*
|
2006-11-16 |
2010-04-08 |
Abbott Laboratories |
Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
US20100260832A1
(en)
*
|
2007-06-27 |
2010-10-14 |
Poniard Pharmaceuticals, Inc. |
Combination therapy for ovarian cancer
|
JP2010533714A
(ja)
*
|
2007-07-16 |
2010-10-28 |
ポニアード ファーマシューティカルズ, インコーポレイテッド |
ピコプラチンのための経口製剤
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
NZ601350A
(en)
*
|
2007-11-16 |
2013-08-30 |
Abbvie Inc |
Method of treating arthritis
|
US20090149461A1
(en)
*
|
2007-12-06 |
2009-06-11 |
Abbott Laboratories |
Method of treating cancer
|
US20120156134A1
(en)
|
2007-12-20 |
2012-06-21 |
Shayne Squires |
Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
|
CN101220008B
(zh)
*
|
2008-01-21 |
2011-04-27 |
中国科学院广州生物医药与健康研究院 |
化合物abt-263的合成方法
|
JP2011511072A
(ja)
*
|
2008-02-08 |
2011-04-07 |
ポニアード ファーマシューティカルズ, インコーポレイテッド |
結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用
|
EP2297103B1
(en)
|
2008-06-09 |
2012-01-04 |
Bristol-Myers Squibb Company |
Hydroxyphenylsulfonamides as antiapoptotic bcl inhibitors
|
US8168784B2
(en)
*
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
UA108193C2
(uk)
*
|
2008-12-04 |
2015-04-10 |
|
Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
|
US8557983B2
(en)
|
2008-12-04 |
2013-10-15 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US20100160322A1
(en)
|
2008-12-04 |
2010-06-24 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
EP2376480B1
(en)
*
|
2008-12-05 |
2016-06-01 |
AbbVie Inc. |
Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
US8586754B2
(en)
*
|
2008-12-05 |
2013-11-19 |
Abbvie Inc. |
BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
US8563735B2
(en)
|
2008-12-05 |
2013-10-22 |
Abbvie Inc. |
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
JP5736318B2
(ja)
|
2008-12-08 |
2015-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌を治療するための化合物
|
CA2747835A1
(en)
*
|
2009-01-19 |
2010-07-22 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
CN102282128B
(zh)
*
|
2009-01-19 |
2015-06-17 |
Abbvie公司 |
用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
|
US20100297194A1
(en)
*
|
2009-04-30 |
2010-11-25 |
Nathaniel Catron |
Formulation for oral administration of apoptosis promoter
|
US20100278921A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Fischer Cristina M |
Solid oral formulation of abt-263
|
US20100280031A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Paul David |
Lipid formulation of apoptosis promoter
|
US8362013B2
(en)
*
|
2009-04-30 |
2013-01-29 |
Abbvie Inc. |
Salt of ABT-263 and solid-state forms thereof
|
US8728516B2
(en)
*
|
2009-04-30 |
2014-05-20 |
Abbvie Inc. |
Stabilized lipid formulation of apoptosis promoter
|
KR101920202B1
(ko)
*
|
2009-05-26 |
2018-11-21 |
애브비 아일랜드 언리미티드 컴퍼니 |
암,면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
|
US9034875B2
(en)
|
2009-05-26 |
2015-05-19 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US20220315555A1
(en)
|
2009-05-26 |
2022-10-06 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8546399B2
(en)
|
2009-05-26 |
2013-10-01 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
TWI532484B
(zh)
|
2009-06-08 |
2016-05-11 |
艾伯維有限公司 |
包含凋亡促進劑之固態分散劑
|
TWI471321B
(zh)
*
|
2009-06-08 |
2015-02-01 |
Abbott Gmbh & Co Kg |
Bcl-2族群抑制劑之口服醫藥劑型
|
AU2010260226A1
(en)
*
|
2009-06-18 |
2012-02-02 |
Abbvie Inc. |
Stable nanoparticulate drug suspension
|
PT2470166E
(pt)
*
|
2009-08-24 |
2013-10-02 |
Lundbeck & Co As H |
Novas composições de 1-[2-(2,4-dimetil-fenilsulfanil)- fenil]piperazina
|
NZ598461A
(en)
*
|
2009-09-20 |
2013-12-20 |
Abbvie Inc |
Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
|
SG10201500152UA
(en)
*
|
2009-12-22 |
2015-03-30 |
Abbvie Inc |
Abt-263 capsule
|
US8710035B2
(en)
|
2010-03-24 |
2014-04-29 |
The University Of Chicago |
Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
|
AU2014202478B2
(en)
*
|
2010-03-25 |
2016-04-28 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
PT2550258E
(pt)
*
|
2010-03-25 |
2015-11-30 |
Abbvie Inc |
Agentes indutores de apoptose para o tratamento de cancro e de doenças imunitárias e autoimunes
|
CN101798292A
(zh)
*
|
2010-03-29 |
2010-08-11 |
无锡好芳德药业有限公司 |
ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
|
TWI520960B
(zh)
|
2010-05-26 |
2016-02-11 |
艾伯維有限公司 |
用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
|
EA031737B1
(ru)
|
2010-06-03 |
2019-02-28 |
Фармасайкликс, Инк. |
Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
|
TWI535712B
(zh)
*
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
RU2598345C2
(ru)
|
2010-10-29 |
2016-09-20 |
Эббви Инк. |
Твердые дисперсии, содержащие средства, вызывающие апоптоз
|
BR112013012740A2
(pt)
|
2010-11-23 |
2016-09-13 |
Abbvie Inc |
sais e formas cristalinas de um agente que induz apoptose
|
PT2642999T
(pt)
*
|
2010-11-23 |
2017-01-05 |
Abbvie Ireland Unlimited Co |
Métodos de tratamento que utilizam inibidores seletivos de bcl-2
|
EP2668180B1
(en)
|
2011-01-25 |
2018-08-01 |
The Regents of The University of Michigan |
Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
|
EP2672969A4
(en)
*
|
2011-02-01 |
2014-07-16 |
Glaxosmithkline Intellectual Property Ltd |
ASSOCIATION
|
WO2012177927A1
(en)
|
2011-06-21 |
2012-12-27 |
Mayo Foundation For Medical Education And Research |
Transgenic animals capable of being induced to delete senescent cells
|
CN104039797B
(zh)
*
|
2011-10-12 |
2016-06-01 |
南京奥昭生物科技有限公司 |
作为细胞凋亡诱导剂的杂环分子
|
CN103127510B
(zh)
*
|
2011-11-30 |
2015-03-25 |
北京天和瑞通科技发展有限公司 |
含有肝细胞生长因子受体抑制剂和Bcl-2抑制剂的药物组合物及其应用
|
MX2014007093A
(es)
|
2011-12-13 |
2014-10-13 |
Buck Inst For Res On Aging |
Metodos para mejorar terapias medicas.
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
WO2013158664A2
(en)
|
2012-04-17 |
2013-10-24 |
Kythera Biopharmaceuticals, Inc. |
Use of engineered viruses to specifically kill senescent cells
|
US8859774B2
(en)
|
2012-05-25 |
2014-10-14 |
Corcept Therapeutics, Inc. |
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
|
US9901080B2
(en)
|
2012-08-23 |
2018-02-27 |
Buck Institute For Research On Aging |
Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
|
US9901081B2
(en)
|
2012-08-23 |
2018-02-27 |
Buck Institute For Research On Aging |
Transgenic mouse for determining the role of senescent cells in cancer
|
SG11201505525UA
(en)
|
2013-01-16 |
2015-08-28 |
Univ Michigan |
Bcl-2bcl-xl inhibitors and therapeutic methods using the same
|
US20140275082A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US20140279528A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Motorola Mobility Llc |
Wearable Authentication Device
|
AU2014296308C1
(en)
|
2013-07-30 |
2018-09-13 |
Kronos Bio, Inc. |
Polymorph of Syk inhibitors
|
US10071130B2
(en)
|
2013-12-12 |
2018-09-11 |
The University Of Chicago |
Methods and compositions related to Hsp90 inhibitors and breast cancer
|
TWI662037B
(zh)
|
2013-12-23 |
2019-06-11 |
美商基利科學股份有限公司 |
脾酪胺酸激酶抑制劑
|
AU2015211021B2
(en)
*
|
2014-01-28 |
2020-07-02 |
Buck Institute For Research On Aging |
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
|
WO2015116735A1
(en)
|
2014-01-28 |
2015-08-06 |
Mayo Foundation For Medical Education And Research |
Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
|
CN106661039B
(zh)
|
2014-02-28 |
2019-09-13 |
林伯士拉克许米公司 |
酪氨酸蛋白质激酶2(tyk2)抑制剂和其用途
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
BR112016028641A2
(pt)
|
2014-07-14 |
2017-08-22 |
Gilead Sciences Inc |
?método para tratar câncer?
|
WO2016023082A1
(en)
|
2014-08-12 |
2016-02-18 |
Monash University |
Lymph directing prodrugs
|
TW201639573A
(zh)
|
2015-02-03 |
2016-11-16 |
吉李德科學股份有限公司 |
有關治療癌症之合併治療
|
WO2016131100A1
(en)
*
|
2015-02-18 |
2016-08-25 |
The Walter And Eliza Hall Institute Of Medical Research |
Methods of treating infectious diseases
|
WO2016138352A1
(en)
|
2015-02-27 |
2016-09-01 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
US10195213B2
(en)
|
2015-03-13 |
2019-02-05 |
Unity Biotechnology, Inc. |
Chemical entities that kill senescent cells for use in treating age-related disease
|
ES2965461T3
(es)
|
2015-08-03 |
2024-04-15 |
Biokine Therapeutics Ltd |
Inhibidor de CXCR4 para el tratamiento del cáncer
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
AU2016318229A1
(en)
|
2015-09-08 |
2018-03-29 |
Monash University |
Lymph directing prodrugs
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
SI3364958T1
(sl)
|
2015-10-23 |
2023-05-31 |
Navitor Pharmaceuticals, Inc. |
Modulatorji interakcije sestrina in gator2 ter njihova uporaba
|
EP3389664A4
(en)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
|
US11111259B2
(en)
|
2015-12-18 |
2021-09-07 |
Unity Biotechnology, Inc. |
Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
|
CN116211803A
(zh)
|
2016-01-11 |
2023-06-06 |
梅里麦克制药股份有限公司 |
抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR)
|
JP2019501225A
(ja)
*
|
2016-01-11 |
2019-01-17 |
メリマック ファーマシューティカルズ インコーポレーティッド |
B細胞リンパ腫2(bcl−2)及び関連タンパク質の阻害
|
WO2017156179A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
WO2017156165A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
SG11201807972YA
(en)
|
2016-03-15 |
2018-10-30 |
Oryzon Genomics Sa |
Combinations of lsd1 inhibitors for the treatment of hematological malignancies
|
KR102511024B1
(ko)
|
2016-03-15 |
2023-03-16 |
오리존 지노믹스 에스.에이. |
고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
|
CA3018932C
(en)
|
2016-03-28 |
2021-10-26 |
Presage Biosciences, Inc. |
Pharmaceutical combinations for the treatment of cancer
|
JP2019510785A
(ja)
|
2016-04-08 |
2019-04-18 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
癌を処置する方法
|
JP6936498B2
(ja)
|
2016-04-21 |
2021-09-15 |
バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーBioVentures, LLC |
抗アポトーシス性Bcl−2ファミリータンパク質の分解を誘導する化合物及びその使用
|
CN116554168A
(zh)
|
2016-06-21 |
2023-08-08 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
US11332470B2
(en)
|
2016-06-21 |
2022-05-17 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
CA3027495A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
CN109952303B
(zh)
|
2016-10-14 |
2022-10-21 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
AU2017345736B2
(en)
|
2016-10-21 |
2022-04-07 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
WO2018085069A1
(en)
|
2016-11-03 |
2018-05-11 |
Gilead Sciences, Inc. |
Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
|
US10414727B2
(en)
|
2016-11-08 |
2019-09-17 |
Navitor Pharmaceuticals, Inc. |
Phenyl amino piperidine mTORC inhibitors and uses thereof
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
EP3565638B8
(en)
|
2017-01-06 |
2024-04-10 |
BicycleRD Limited |
Bicycle conjugate for treating cancer
|
JOP20190191A1
(ar)
|
2017-02-22 |
2019-08-08 |
Astrazeneca Ab |
وحدات شجرية علاجية
|
CA3055209A1
(en)
|
2017-03-08 |
2018-09-13 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors, uses, and methods for production thereof
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
KR102342620B1
(ko)
|
2017-03-31 |
2021-12-22 |
코어셉트 쎄라퓨틱스 인코포레이티드 |
자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
CN116370448A
(zh)
|
2017-04-26 |
2023-07-04 |
纳维托制药有限公司 |
Sestrin-gator2相互作用的调节剂及其用途
|
US11046698B2
(en)
|
2017-07-28 |
2021-06-29 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
CN115028640A
(zh)
|
2017-08-25 |
2022-09-09 |
吉利德科学公司 |
Syk抑制剂的多晶型物
|
EP3675838A4
(en)
|
2017-08-29 |
2021-04-21 |
PureTech LYT, Inc. |
LIPID PRODUCTS DIRECTED TO THE LYMPHATIC SYSTEM
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス, インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES
|
JP2021508703A
(ja)
|
2017-12-26 |
2021-03-11 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak分解剤およびそれらの使用
|
CN111801320A
(zh)
|
2018-01-10 |
2020-10-20 |
里科瑞尔姆Ip控股有限责任公司 |
苯甲酰胺化合物
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
CA3089762A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
WO2019148136A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
IL301120A
(en)
|
2018-02-27 |
2023-05-01 |
Artax Biopharma Inc |
A history of novel chromium as TCR–NCK interaction inhibitors
|
TW202002952A
(zh)
|
2018-03-15 |
2020-01-16 |
美商艾伯維有限公司 |
用於治療胰臟癌之abbv-621與抗癌劑之組合
|
AR114828A1
(es)
|
2018-04-24 |
2020-10-21 |
Vertex Pharma |
Compuestos de pteridinona y sus usos
|
TWI813673B
(zh)
|
2018-04-24 |
2023-09-01 |
德商馬克專利公司 |
抗增生化合物及其用途
|
BR112020022092A2
(pt)
|
2018-04-29 |
2021-02-02 |
Beigene, Ltd. |
compostos, método para tratar doenças apoptóticas desreguladas e composição farmacêutica
|
JP7382353B2
(ja)
|
2018-06-15 |
2023-11-16 |
ヤンセン ファーマシューティカ エヌ.ベー. |
ラパマイシン類似体およびその使用
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
US11491168B2
(en)
|
2018-07-31 |
2022-11-08 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
TWI824010B
(zh)
|
2018-09-18 |
2023-12-01 |
加拿大商聖諾康生命科學公司 |
治療血癌之組合療法
|
US11414431B2
(en)
|
2018-10-15 |
2022-08-16 |
Nimbus Lakshmi, Inc. |
Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors
|
EP3870158A4
(en)
|
2018-10-24 |
2022-08-10 |
Navitor Pharmaceuticals, Inc. |
POLYMORPHIC COMPOUNDS AND USES THEREOF
|
KR20210111252A
(ko)
|
2018-11-30 |
2021-09-10 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
EP3886843A4
(en)
|
2018-11-30 |
2022-08-31 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND THEIR USES
|
KR102657097B1
(ko)
|
2018-12-19 |
2024-04-15 |
코어셉트 쎄라퓨틱스 인코포레이티드 |
헤테로아릴-케톤 융합 아자데칼린 화합물인 렐라코릴란트를 함유하는 약학적 제제
|
WO2020132046A1
(en)
|
2018-12-19 |
2020-06-25 |
Corcept Therapeutics Incorporated |
Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
|
US11234971B2
(en)
|
2018-12-19 |
2022-02-01 |
Corcept Therapeutics Incorporated |
Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
JP2022518505A
(ja)
|
2019-01-23 |
2022-03-15 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
MX2021010135A
(es)
|
2019-02-22 |
2021-09-23 |
Corcept Therapeutics Inc |
Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona.
|
EP3927708A1
(en)
|
2019-02-22 |
2021-12-29 |
Kronos Bio, Inc. |
Solid forms of condensed pyrazines as syk inhibitors
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
WO2020206424A1
(en)
|
2019-04-05 |
2020-10-08 |
Kymera Therapeutics, Inc. |
Stat degraders and uses thereof
|
CN114502540A
(zh)
|
2019-05-31 |
2022-05-13 |
医肯纳肿瘤学公司 |
Tead抑制剂和其用途
|
KR20220034782A
(ko)
|
2019-06-12 |
2022-03-18 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 매개 세포 독성 요법 및 친생존 bcl2 패밀리 단백질 억제제의 병용 요법
|
JP2022548594A
(ja)
|
2019-09-11 |
2022-11-21 |
ビンシア・バイオサイエンシーズ・インコーポレイテッド |
Usp30阻害剤及びその使用
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
MX2022005215A
(es)
|
2019-11-01 |
2022-06-08 |
Navitor Pharm Inc |
Metodos de tratamiento que usan un modulador de la diana mecanicista del complejo 1 de rapamicina (mtorc1).
|
BR112022008683A2
(pt)
|
2019-11-05 |
2022-07-19 |
Abbvie Inc |
Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax
|
EP4069223A4
(en)
|
2019-12-05 |
2023-12-20 |
Janssen Pharmaceutica NV |
RAPAMYCIN ANALOGS AND THEIR USES
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
TW202136251A
(zh)
|
2019-12-17 |
2021-10-01 |
美商凱麥拉醫療公司 |
Irak降解劑及其用途
|
BR112022012410A2
(pt)
|
2019-12-23 |
2022-08-30 |
Kymera Therapeutics Inc |
Degradadores smarca e usos dos mesmos
|
EP4100017A4
(en)
|
2020-02-05 |
2024-04-10 |
PureTech LYT, Inc. |
LIPID PRODRUGS OF NEUROSTEROIDS
|
EP4114529A1
(en)
|
2020-03-03 |
2023-01-11 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
IL296451A
(en)
|
2020-03-19 |
2022-11-01 |
Kymera Therapeutics Inc |
mdm2 joints and their uses
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
WO2021233948A1
(en)
|
2020-05-19 |
2021-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat a pathogen lung infection
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
US20230270816A1
(en)
|
2020-07-06 |
2023-08-31 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
|
KR20230044480A
(ko)
|
2020-07-30 |
2023-04-04 |
카이메라 쎄라퓨틱스 인코포레이티드 |
돌연변이 림프종의 치료 방법
|
AU2021327130A1
(en)
|
2020-08-17 |
2023-03-02 |
Bicycletx Limited |
Bicycle conjugates specific for Nectin-4 and uses thereof
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
IL303376A
(en)
|
2020-12-02 |
2023-08-01 |
Ikena Oncology Inc |
TEAD inhibitors and their uses
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
BR112023015590A2
(pt)
|
2021-02-02 |
2023-10-17 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 e usos dos mesmos
|
CA3207380A1
(en)
|
2021-02-15 |
2022-08-18 |
Haojing RONG |
Irak4 degraders and uses thereof
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
KR20230172548A
(ko)
|
2021-04-16 |
2023-12-22 |
이케나 온콜로지, 인코포레이티드 |
Mek 억제제 및 이의 용도
|
CN118103368A
(zh)
|
2021-08-25 |
2024-05-28 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
GB202201824D0
(en)
|
2022-02-11 |
2022-03-30 |
Genome Res Ltd |
Methods of treatment
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
TW202400589A
(zh)
|
2022-05-06 |
2024-01-01 |
美商樹線生物科學公司 |
四氫異喹啉異雙功能bcl—xl降解劑
|
WO2023215449A1
(en)
|
2022-05-06 |
2023-11-09 |
Treeline Biosciences, Inc. |
Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
|
WO2023215471A1
(en)
|
2022-05-06 |
2023-11-09 |
Treeline Biosciences, Inc. |
Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
TW202404581A
(zh)
|
2022-05-25 |
2024-02-01 |
美商醫肯納腫瘤學公司 |
Mek抑制劑及其用途
|
WO2024012557A1
(en)
*
|
2022-07-15 |
2024-01-18 |
Berrybio (Hong Kong) Limited |
Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
TW202415650A
(zh)
|
2022-08-02 |
2024-04-16 |
英商利米那生物科技有限公司 |
芳基-***基及相關gpr84拮抗劑及其用途
|
US20240208961A1
(en)
|
2022-11-22 |
2024-06-27 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|